Hosted on MSN

Johnson & Johnson raises 2026 outlook to $11.30-$11.50 EPS and $100.2B sales midpoint while targeting $100B annual revenue

"We said 2026 would be a year of accelerated growth and impact for Johnson & Johnson. And with our strong Q1 performance, including our beat on consensus and raised guidance, you can see we are ...

Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance

Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as ...
Hosted on MSN

J&J CEO now sees 'line of sight' to double-digit growth for his $100 billion company. Here's why investors should pay attention.

Johnson & Johnson is on pace to generate roughly $100 billion in revenue in 2026. The company believes it has a unique opportunity to invest in its future today. 10 stocks we like better than Johnson ...
Seeking Alpha

J&J avoiding GLP-1 space to focus on cancer drugs

Johnson & Johnson (JNJ) CEO Joaquin Duato says his company has no plans to venture into the fast-growing market for GLP-1 obesity drugs and will instead focus on treatments for conditions such as ...
Wall Street Journal

Johnson & Johnson CEO Joaquin Duato on Fighting Cancer, AI and Medical Innovation

On this Leaders episode, recorded at the 2026 WSJ CEO Council Summit in London, Johnson & Johnson Chairman and CEO Joaquin Duato joins WSJ Leadership Institute President Alan Murray to discuss the ...